-
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
Monday, May 1, 2023 - 12:54pm | 440Read More...Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD) operations. The BIIB Analyst: Yatin Suneja upgraded Biogen to a Buy from a Neutral rating, with a $...
-
Analyst On La Jolla's Hypotension Drug: We Expect Approval Next Year
Monday, May 22, 2017 - 11:23am | 611Read More...Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC-501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018. The Study And The Results The full data from the Phase III study,...
-
Ariad Pharmaceuticals Expected To See Clinical Catalysts
Wednesday, October 5, 2016 - 1:21pm | 319Read More...SunTrust Robinson Humphrey sees potential upside of 65 percent in Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) given clinical catalysts and the company could be a takeover target. Ariad's lead product Iclusig is a potent chronic myeloid leukemia (CML), drug, with the potential for broader use...
